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One- vs. Three-Fraction Pancreatic 
stereotactic Body radiation Therapy 
for Pancreatic carcinoma: single 
institution retrospective review
Philip Anthony Sutera1, Mark E. Bernard2, Beant S. Gill1, Kamran K. Harper1,  
Kimmen Quan1, Nathan Bahary3, Steven A. Burton1, Herbert Zeh4 and Dwight E. Heron1*
1 Department of Radiation Oncology, Hillman Cancer Center, Pittsburgh, PA, United States, 2 Department of Radiation 
Medicine, University of Kentucky, Lexington KY, 3 Department of Medical Oncology, Hillman Cancer Center, Pittsburgh,  
PA, United States, 4 Department of Surgical Oncology, Hillman Cancer Center, Pittsburgh, PA, United States
Background/introduction: Early reports of stereotactic body radiation therapy (SBRT) 
for pancreatic ductal adenocarcinoma (PDAC) used single fraction, but eventually shifted 
to multifraction regimens. We conducted a single institution review of our patients treated 
with single- or multifraction SBRT to determine whether any outcome differences existed.
Methods and materials: Patients treated with SBRT in any setting for PDAC at our 
facility were included, from 2004 to 2014. Overall survival (OS), local control (LC), regional 
control (RC), distant metastasis (DM), and late grade 3 or greater radiation toxicities from 
the time of SBRT were calculated using Kaplan–Meier estimation to either the date of 
last follow-up/death or local/regional/distant failure.
results: We identified 289 patients (291 lesions) with pathologically confirmed PDAC. 
Median age was 69 (range, 33–90) years. Median gross tumor volume was 12.3 (8.6–
21.3) cm3 and planning target volume 17.9 (12–27) cm3. Single fraction was used in 90 
(30.9%) and multifraction in 201 (69.1%) lesions. At a median follow-up of 17.3 months 
(IQR 10.1–29.3  months), the median survival for the entire cohort 17.8  months with 
a 2-year OS of 35.3%. Univariate analysis showed multifraction schemes to have a 
higher 2-year OS 30.5% vs. 37.5% (p = 0.019), it did not hold significance on MVA. 
Multifractionation schemes were found to have a higher LC on MVA (HR = 0.53, 95% CI, 
0.33–0.85, p = 0.009). At 2 years, late grade 3+ toxicity was 2.5%. Post-SBRT CA19-9 
was found on MVA to be a prognostic factor for OS (HR = 1.01, 95% CI, 1.01–1.01, 
p = 0.009), RC (HR = 1.01, 95% CI 1.01–1.01, p = 0.02), and DM (HR = 1.01, 95% CI, 
1.01–1.01, p = 0.001).
conclusion: Our single institution retrospective review is the largest to date comparing 
single and multifraction SBRT and the first to show multifraction regimen SBRT to have a 
higher LC than single fractionation. Additionally, we show low rates of severe late toxicity 
with SBRT.
Keywords: pancreatic adenocarcinoma, stereotactic body radiation therapy, overall survival, local control, 
fractionation, toxicity
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inTrODUcTiOn
Pancreatic carcinoma is an aggressive malignancy with a pre-
dicted 53,070 new cases and 41,780 deaths in the US in 2016 with 
a 5-year survival of only 7% (1). Currently, tumor resectability is 
the single most powerful prognostic factor with surgery allowing 
the only practical chance for cure (2). Systemic chemotherapy 
and radiation, however, have been shown to play an important 
role as adjuvant therapy. Unfortunately, less than 20% of patients 
are deemed surgical candidates at time of presentation due to the 
commonly advanced presentation of disease (3, 4).
Historically, radiation therapy for pancreatic adenocarcinoma 
consisted of 6 weeks of external beam radiation therapy (EBRT) 
which was associated with significant toxicity and delayed time 
to systemically dosed chemotherapy (5). Drawing upon the 
success of stereotactic radiosurgery in the treatment of intrac-
ranial tumors, stereotactic body radiation therapy (SBRT) was 
developed in order to deliver a hypofractioned treatment to 
extracranial tumors (6, 7). Using high precision, this can deliver 
a high biological effective dose to the tumor while minimizing 
dose to surrounding tissue (8).
Recently, SBRT has demonstrated utility as primary treat-
ment in unresectable disease, neoadjuvant treatment in locally 
advanced disease, and adjuvant therapy for resected and recur-
rent pancreatic tumors (9–14). Due to the shorter duration of 
treatment in SBRT over standard EBRT, patients receive full dose 
systemic chemotherapy with less delay. Importantly, studies show 
SBRT to have excellent local control (LC) and minimal toxicity 
rates while remaining a cost-effective treatment option (15–17). 
Initial experience with SBRT for pancreatic adenocarcinoma 
primarily used single fraction regimens however were compli-
cated by relatively high rates of late GI toxicity (11, 18, 19). Later 
experiences used multifraction regimens were implemented and 
have since been shown to limit late GI toxicity (20). Data compar-
ing single- to multifraction regimens, however remain limited 
and are unclear whether there are any other differences in these 
treatments besides toxicity rates. We therefore aim to compare 
single to multifraction SBRT for pancreatic cancer to distinguish 
possible differences in control rates, overall survival (OS), and 
toxicity.
MaTerials anD MeThODs
Patient Population
Following approval from our institutional review board, we 
reviewed patients with histologically proven pancreatic adeno-
carcinoma treated with SBRT in either one or three fractions 
between 2004 and 2014. Patients received SBRT as neoadjuvant, 
adjuvant, or definitive treatment. Patients with resectable, 
borderline resectable, unresectable, medically inoperable, and 
recurrent tumors were included in this study. Patients with dis-
tant metastasis (DM) at diagnosis (who were provided SBRT for 
symptom control) were excluded as well as one additional patient 
excluded for having no records other than SBRT date and dose. 
Patients included in the study were staged clinically, with the use 
of CT scans and endoscopic ultrasound techniques. SBRT was 
performed on either a CyberKnife robotic radiosurgery (Accuray 
Inc., Sunnyvale, CA, USA) or non-robotic linear accelerator 
based platforms (Trilogy, TrueBeam) (Varian Medical Systems, 
Palo Alto, CA, USA). Patient variables including age, race, gender, 
SMAD4 mutation, surgical status, chemotherapy treatment, prior 
EBRT, and SBRT dose, dosimetry, and advanced toxicities were 
collected.
Definition of Parameters
Resectable status was determined by a multidisciplinary case 
review using NCCN guidelines for resectable, borderline resect-
able, and unresectable disease. Local, regional, and distant 
progression were determined based on radiographic findings on 
follow up and/or confirmatory biopsy if done. Local progression 
was identified as progressive disease using RECIST 1.1 criteria. 
This is characterized by at least a 20% increase in the sum of 
diameters of the tumor with minimum of a 5 mm increase (21). 
Regional failure was defined as disease progression to the regional 
nodes defined as n1, n2, or n3 by the JPS classification (22, 23) 
(or new tumor growth within the pancreas outside of the radia-
tion field). Toxicity was graded retroactively with the Common 
Terminology Criteria for Adverse Events Version 4.0 (CTCAE 
4.0). Patients included in this review were simulated in the supine 
position using four-dimensional CT scan with IV contrast in a 
vacuum lock bag and wingboard. The 4D-CT scan was obtained 
utilizing 1.25 mm slices simulated in a vacuum lock bag. During 
the time of simulation, a motion study was performed during 
which we obtained multiple images during the respiratory cycle 
using the abdominal marker as a surrogate for the respiratory 
cycle. The signal detected from the abdominal surrogate was used 
to bin the CT images, creating a series of separate CT scans for 
each phase in the breathing cycle. We then contoured the gross 
tumor volume (GTV) to see whether any motion was detected 
during the breathing cycles. If the motion was found to be 
more than 5 mm, we decided to use respiratory gating. In this 
technique, we determined which phases of the breathing cycle 
limit the tumor motion to 5 mm and treat during those specific 
phases. During the patient’s treatment, an equivalent abdominal 
surrogate signal is used to control the beam on time of the linear 
accelerator. The GTV was determined based on the simulation 
CT scan and diagnostic CT scans. The planning target volume 
(PTV) margin was added to be approximately 3 mm from GTV 
with editing off of the bowel (Figure 1). Patients included in the 
study had fiducials placed before CT-simulation to assist with 
target delineation during treatment. The bowel was our major 
dose limiting structured and was limited to no more than 30 Gy 
maximum. The max dose for the kidneys, liver, and cord were 
limited to 15, 50, and 15 Gy, respectively. Notably two patients 
exceeded the max dose for the right kidney (29.0 and 18.3 Gy), 
and one patient exceeded the max dose for the cord (27.6 Gy).
statistical analysis
Overall survival, LC, regional control (RC), DM, and advanced 
grade 3 or greater radiation toxicities from the time of SBRT were 
calculated using Kaplan–Meier estimation to either the date of 
last follow-up/death or local/regional/distant failure. Predictive 
factors for OS, LC, RC, DM, and advanced toxicities were deter-
mined through use of univariate log-rank test or Cox regression 
FigUre 1 | Example stereotactic body radiation therapy plan for pancreatic adenocarcinoma with gross tumor volume highlighted in red, planning target volume 
highlighted in orange and 85% isodose highlighted in dose heatmap.
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analysis. Those variables deemed significant (p  <  0.05) were 
incorporated into multivariable survival analyses using forward 
stepwise selection in a Cox proportional hazards regression 
model. Statistical significance was set with a two-sided p-value 
of <0.05. Statistical analysis was performed using IBM SPSS 
Statistics version 23.
resUlTs
Patient characteristics
A detailed list of patient characteristics can be found in Table 1. 
We identified 289 patients with 291 lesions treated with SBRT 
of pancreatic adenocarcinoma with a median age at diagnosis of 
69 (range 33–90) with 49.8% female and 50.2% male. Tumors 
were located in the head (62.9%), body (11%), uncinate process 
(7.6%), neck (4.8%), tail (2.7%), and genu (0.3%) of the pancreas. 
Multifocal disease as defined by two or more lesions within the 
pancreas was seen in 10.7%. SMAD4 mutation status was col-
lected and positive in 10% and unknown in 78.7% of lesions. 
Recurrent lesions represented 13.4% of the total and 13.1% of the 
total lesions received prior EBRT with a median dose of 50.4 Gy 
in 2–8 fractions (IQR, 30–50.4). Chemotherapy was given to 
82.1% of patients and 55.0% received neoadjuvant chemotherapy. 
Surgical status at diagnosis, deemed in a multidisciplinary case 
review, included resectable (entire cohort: 39.2%, single frac-
tion: 41.3%, multifraction: 37.7%), borderline resectable (entire 
cohort: 14.0%, single fraction: 2.2%, multifraction: 19.1%), 
locally advanced/unresectable (entire cohort: 42.3%, single 
fraction: 55.4%, multifraction:37.2%), and medically inoperable 
(entire cohort:4.5%, single fraction: 1.1%, multifraction: 6.0). 
Surgical resection was performed on 46.7, 44.6, and 47.7% of the 
entire cohort, single fraction patients, and multifraction patients, 
respectively.
sBrT Treatment characteristics
Stereotactic body radiation therapy was delivered by Trilogy 
(41.2%), Truebeam (34.1%), or CyberKnife (24.7%) in either one 
fraction (30.9%) or multiple fractions (69.1%). Median dose was 
24 Gy (range 18–25) for single fraction and 36 Gy (range 24–36) for 
three fractions. One patient received 24 Gy in two fractions with 
all others receiving three-fraction regimens if treated in multiple 
fractions. For the entire cohort, GTV was 12.3 cm3 (IQR 8.6–21.3) 
and PTV was 17.9 cm3 (IQR 12–17). For patients who received 
neoadjuvant SBRT, the median time to surgery was 1.8 months 
(IQR 1.44–3.84). For those who received adjuvant SBRT, the 
median time from surgery was 3.77 months (IQR 2.17–12.15).
Overall survival
At a median follow-up of 17.3 months (IQR 10.1–29.3 months), 
the median survival for the entire cohort was 17.8 months with a 
2-year OS of 35.3% (Table 2). Univariate analysis demonstrated 
superior 2-year survival was significantly associated with age 
(p < 0.001), pre-SBRT CA19-9 (p < 0.001), post-SBRT CA19-9 
(p =  0.011), non-robotic treatment platform (p =  0.013), PTV 
volume (p  <  0.001), recurrent lesions (p  =  0.001), surgery 
(p < 0.001), and multifraction SBRT (p = 0.019). While univariate 
analysis showed multifraction schemes to have a higher 2-year 
OS 30.5% vs. 37.5%, it did not hold significance on multivariate 
analysis. Only surgery [p = < 0.001, HR 0.31 (95% CI, 0.19–0.51)] 
and post-SBRT CA19-9 [p = 0.009, HR 1.01 (95% CI, 1.01–1.01)] 
maintained significance on multivariate analysis (Table 3). For 
patients receiving resection, 2-year OS was 59.8% compared to 
14.3% for those not receiving surgical resection.
local control
Two-year LC was 66.1% for the entire cohort, 56.8% for single 
fraction, and 69.7% for multifraction SBRT (Figure 2). Univariate 
characteristics Value (n = 291 lesions)
No 252 (86.6%)
gTV (cm3) (median, iQr) 12.3 (8.6–21.3)
PTV (cm3) (median, iQr) 17.9 (12–27)
Fractionation
Single 90 (30.9%)
Multifraction 201 (69.1%)
Dose
18 Gy in 1 fraction 2 (0.7%)
20 Gy in 1 fraction 4 (1.4%)
20 Gy in 2 fractions 1 (0.3%)
22 Gy in 1 fraction 17 (5.8%)
24 Gy in 1 fraction 62 (21.3%)
24 Gy in 2 fraction 1 (0.3%)
24 Gy in 3 fraction 2 (0.7%)
25 Gy in 1 fraction 5 (1.7%)
27 Gy in 3 fractions 7 (2.4%)
30 Gy in 3 fractions 28 (9.6%)
36 Gy in 3 fractions 162 (55.7%)
BeD10 gy
Median (IQ range) 180 Gy10 (180–183.3)
aPercentages out of the 92 patients who received single-fraction SBRT.
bPercentages out of the 199 patients who received multifraction SBRT.
SBRT, stereotactic body radiation therapy.
TaBle 1 | Patient characteristics.
characteristics Value (n = 291 lesions)
age (years, range) 69 (33–90)
gender
Female 145 (49.8%)
Male 146 (50.2%)
ca19-9 value (median value, iQr)
At diagnosis 221(80–733)
Pre-SBRT 81 (21–378)
Post-SBRT 73 (23–342)
sMaD4 mutated
No 33 (11.3%)
Yes 29 (10%)
Unknown 229 (78.7%)
surgical status
Resectable entire cohort 112 (39.2%)
Resectable single fraction 38 (41.3%)a
Resectable multifraction 75 (37.6%)b
Borderline resectable 40 (14.0%)
Borderline resectable single fraction 2 (2.2%)a
Borderline resectable multifraction 38 (19.1%)b
Unresectable 121 (41.5%)
Unresectable single fraction 51 (55.4%)a
Unresectable multifraction 74 (37.2%)b
Medically inoperable 13 (4.5%)
Medically inoperable single fraction 1 (1.1%)a
Medically inoperable multifraction 12 (6.0%)b
surgery
Yes entire cohort 136 (46.7%)
Yes single fraction 41 (44.6%)a
Yes multifraction 95 (47.7%)b
No entire cohort 155 (53.3%)
No single fraction 51 (55.4%)a
No multifraction 105 (52.3%)b
any chemotherapy
Yes 239 (82.1%)
No 42 (14.4%)
Unknown 10 (3.4%)
neoadjuvant chemotherapy
Yes 160 (55%)
No 115 (39.5%)
Unknown 16 (5.5%)
location
Body 32 (11%)
Heal 183 (62.9%)
Tail 8 (2.7%)
Uncinate 22 (7.6%)
Neck 14 (4.8%)
Genu 1 (0.3%)
Multiple 31 (10.7%)
Prior eBrT
Yes 38 (13.1%)
No 253 (86.9%)
Previous EBRT dose (median, IQR) 50.4 (30–50.4)
Treatment platform
Trilogy 120 (41.2%)
CyberKnife 72 (24.7%)
Truebeam 99 (34%)
recurrent lesion
Yes 39 (13.4%)
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analysis demonstrated superior 2-year LC significantly asso-
ciated with treatment platform (p  =  0.002), non-recurrent 
lesions (p < 0.001), surgery (p = 0.01), and multifraction SBRT 
(p  =  0.004). Two-year LC for patients who received surgical 
resection was 74.1 vs. 53.9% for those who did not. On multi-
variate analysis, multifractionation [p = 0.009, HR 0.53 (95% CI, 
0.33–0.85)] was associated with higher LC, whereas recurrent 
lesions led to lower LC [p = 0.003, HR 2.31 (95% CI, 1.32–4.05)] 
(Table 4). Two-year LC for recurrent lesions was 35.4% compared 
to 70.4% for non-recurrent lesions.
rc and Distant Metastases
One- and two-year RC rates were 89.2 and 86.3%, respectively. 
A higher post-SBRT CA19-9 was the only variable found to 
be significantly associated with inferior RC on univariate and 
multivariate analysis [p  =  0.02, HR 1.01 (95% CI, 1.01–1.01)] 
(Table  5). At one and two years, the Kaplan–Meier estimated 
rate of DM was 39.5 and 56.4%, respectively. Univariate analysis 
identified CA19-9 at diagnosis (p = 0.041), pre-SBRT CA 19-9 
(p  =  0.001), and post-SBRT CA 19-9 (p  =  0.006) associated 
with increased distant metastases. Post-SBRT CA19-9 was the 
only variable to maintain significance on multivariate analysis 
[p = 0.001, HR 1.01 (95% CI, 1.01–1.01)] (Table 5). Treatment 
fractionation was not found to be associated with either RC or 
distant metastases.
late radiation Toxicity
For the entire cohort, the Kaplan–Meier estimated advanced 
grade 3+ toxicity rate at 1- and 2-years was 2.5% (95% CI, 
2.3–2.7%) advanced grade. No significant difference was noted 
based on single- or multifraction use (2-year advanced grade 3+ (Continued )
TaBle 1 | Continued
TaBle 2 | Univariate and multivariate analyses for overall survival (OS).
Variable 2-year Os p Value
age – <0.001
ca19-9
At diagnosis – 0.604
Pre-SBRT – <0.001
By median (≤83 vs. <83) – 0.457
≤90 vs. >90 – 0.347
Post-SBRT – 0.011
By median (≤73 vs. >73) 54.1 vs. 26.4% <0.001
≤90 vs. >90 52.1 vs. 25.5% <0.001
SMAD4 mutation 0.968
Location – 0.283
Prior EBRT – 0.241
Treatment platform
All (Trilogy, Truebeam, CK) 39.5 vs. 27.8 vs. 35.9% 0.036
Non-robotic (T/T) vs. CyberKnife 37.9 vs. 27.8% 0.013
All (Trilogy, Truebeam, CK)
recurrent lesion
Recurrent vs. not 69.4 vs. 30.4% 0.001
Surgery (yes vs. no) 59.8 vs. 14.3% <0.001
Dosimetry
GTV volume – 0.399
GTV max dose – 0.163
GTV min dose – 0.793
PTV volume – <0.001
By median (≤18 vs. >18 cm3) 44 vs. 31.9% 0.033
PTV max dose – 0.847
PTV min dose – 0.529
PTV mean dose – 0.982
Small bowel max dose – 0.365
Small bowel mean dose – 0.179
Single vs. multifraction 30.5 vs. 37.5% 0.019
BED10 Gy – 0.151
Variable hr (95% ci) p Value
Post-SBRT CA 19-9 (continuous) 1.01 (1.01–1.01) 0.009
surgery
Not completed 1.00 (reference) –
Completed 0.31 (0.19–0.50) <0.001
Boldface values are significant predictors (p value < 0.05).
TaBle 3 | Univariate and multivariate analysis for local control (LC).
Variable 2-year lc p Value
Age – 0.549
ca 19-9
At diagnosis – 0.581
Pre-SBRT – 0.820
Post-SBRT – 0.082
SMAD4 mutation – 0.791
Location – 0.427
Prior EBRT – 0.586
Treatment platform
All (Trilogy, Truebeam, CK) 73.7 vs. 61.7 vs. 58.5% 0.022
Non-robotic (T/T) vs. CyberKnife 68.2 vs. 58.5% 0.010
All (Trilogy, Truebeam, CK)
recurrent lesion
Recurrent vs. not 35.4 vs. 70.4% <0.001
Surgery (yes vs. no) 74.1 vs. 53.9% 0.010
Dosimetry
GTV volume – 0.419
GTV max dose – 0.145
GTV min dose – 0.223
PTV volume – 0.260
PTV max dose – 0.196
PTV min dose – 0.753
PTV mean dose – 0.213
Small bowel max dose – 0.657
Small bowel mean dose – 0.355
Single vs. multifraction 56.8 vs. 69.7% 0.004
BED10 Gy (continuous) – 0.052
Variable hr (95% ci) p Value
recurrent lesion
No 1.00 (reference) 0.003
Yes 2.31 (1.32–4.05)
Fractionation scheme
Single fraction 1.00 (reference) 0.009
Multifraction 0.53 (0.33–0.85)
Boldface values are significant predictors (p value < 0.05).
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toxicity estimate 2.3 vs. 2.8%, p = 0.747). Prior radiation therapy 
was the only factor predictive of advanced grade 3+ toxicity 
[p = 0.019, HR 4.58 (95% CI, 1.29–16.21)] (Table 6). For patients 
who received surgery, advanced grade 3+ toxicity rate at 2-years 
was 1.8% compared to 3.2% for non-surgical patients (p = 0.258). 
Three patients experienced grade 4 toxicities which included an 
ileal obstruction (n = 1), obstruction gastric (n = 1), and duodenal 
stenosis (n = 1) all requiring urgent operative intervention. Eight 
patients experienced grade 3 toxicities which included nausea 
(n = 3), enteritis (n = 2), enterocolitis (n = 1), ileal hemorrhage 
(n = 1), and biliary tract infection (n = 1).
DiscUssiOn
This retrospective review aimed to assess the role SBRT frac-
tionation on OS and LC of pancreatic adenocarcinoma while 
also determining the rates of late radiation toxicity for this 
treatment modality. This study identified three-fraction SBRT 
provides superior 2-year LC over single fractionation, but may 
not be associated with improved OS. Additionally, treatment 
with either single- or multifraction SBRT was delivered with 
reasonable levels of toxicity with prior radiation therapy most 
predictive of late radiation toxicities. Consistent with numer-
ous other reports, these data also support surgery as the most 
important factor for OS (24).
Pollom et  al. previously reported on 167 patients with unre-
sectable pancreatic adenocarcinoma comparing single- versus 
five-fraction SBRT. Median OS for all patients was 13.6  months 
with 12-month survival from SBRT at 30.8 and 34.9% for sin-
gle- and multifraction, respectively. The 12-month cumulative 
incidence rates of local recurrence were 9.5 and 11.7% for single 
and multifraction, respectively. Neither OS from SBRT nor local 
recurrence demonstrated significant difference between single- 
and multifraction groups. Cumulative GI grade 2+ toxicity by 
12 months was 26.1% for single fraction and 7.8% for multifraction 
which was a significant difference (20). In contrast, our data show 
a significant improvement in LC with multifraction as compared to 
single-fraction regimens. This difference is most likely due to the 
FigUre 2 | Local control for single- and multifraction stereotactic body radiation therapy.
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significantly larger cohort used in the present study. Additional dif-
ferences that may have contributed included our study reporting on 
all pancreatic adenocarcinoma except those with distant metastases 
as opposed to only unresectable tumors including those with dis-
tant metastases at treatment. Additionally, our multifraction group 
consisted of 36 Gy in three fractions as opposed to 33 Gy in five 
fractions. Finally, because the linear quadratic model in not appli-
cable for hypofractionated treatments, there could be a difference 
in BED between these two regimens which is currently unknown.
We believe our difference observed in LC between single and 
multifraction SBRT is most likely a result of differences in tumor 
dose. In our initial experience with single fraction SBRT there 
was significant concern for bowel toxicity. In an effort to reduce 
toxicity, dose to the small bowel was limited therefore compromis-
ing PTV coverage. Multifraction regimens allowed us to be less 
conservative with bowel dosing and therefore allow for greater 
coverage of the tumor. This would further explain why we did not 
observe a difference in advanced grade 3+ toxicity between these 
regimens as demonstrated by Pollom et al. These two studies seem 
to demonstrate the trade-off between toxicity and LC for single 
fraction SBRT. Our observed difference in LC however could also 
be a result of patient demographics independent of fractionation. 
As reports of increased toxicity with single fraction surfaced, our 
institution slowly switched to multifraction regimens. This lead 
a greater proportion of patients treated in later years received 
three-fraction SBRT. It is possible this observed difference was 
a result of differences in chemotherapy; however, chemotherapy 
regimens were poorly reported and demonstrated significant het-
erogeneity between and within single- and multifraction cohorts. 
Additionally, there was higher proportion of recurrent disease 
in those treated with single fraction SBRT. As we have shown, 
patients with recurrent disease demonstrated worse LC which 
may have affected the results observed in single-fraction patients. 
Although surgical resection has been shown to be the most signifi-
cant predictive factor for clinical outcomes, it is unlikely playing a 
role in the observed difference between different fraction regimens 
as resection rates were similar between both groups. SBRT has also 
been an enticing modality in the treatment of locally advanced 
and borderline resectable pancreatic adenocarcinoma due to its 
improved rates of LC and increased rates of resection in these 
tumors (25). Although previous trials analyzing single fraction 
SBRT demonstrated excellent LC, they were associated with 
unacceptable rates of toxicity (18, 19). This leads to the adoption 
of multifraction regimens. Chuong et al. reported on 73 patients 
with borderline resectable (78.1%) and locally advanced (21.9%) 
pancreatic adenocarcinoma treated with induction chemotherapy 
followed by five-fraction SBRT. Borderline resectable and locally 
advanced tumors experienced a median OS of 16.4 and 15 months 
and a 1-year progression free survival of 42.8 and 41%, respec-
tively, with 5.3% advanced grade 3+ toxicity (10). Mahadevan 
et al. reported on 36 patients with nonmetastatic locally advanced 
pancreatic cancer treated with three-fraction SBRT with a total 
dose of 24, 30, or 36 Gy followed by gemcitabine therapy. Median 
OS was 14.3 months; LC was 78% with a median progression-free 
survival of 9.6 months and 5.5% (n = 2) developed advanced grade 
3+ toxicity. Although previous reports identified unacceptable 
rates of advanced toxicity with single-fraction SBRT our results 
demonstrated no significant difference between single- and 
multifractionation on advanced toxicity, which may reflect vari-
ances in volumes, constraints and total dose between institutions. 
Additionally, as previously stated, due to early reports of high 
rates of late GI toxicity, our institution limited dose to the small 
TaBle 5 | Univariate and multivariate analysis for distant metastasis (DM).
Variable 2-year DM p Value
Age – 0.348
ca 19-9
At diagnosis – 0.041
Pre-SBRT – 0.001
By median (≤83 vs. >83) 48.9 vs. 59.8% 0.039
≤ 90 vs. >90 50.3 vs. 59.2% 0.054
Post-SBRT – 0.006
By median (≤73 vs. >73) 41.8 vs. 70.8% 0.004
≤90 vs. >90 47.7 vs. 66.6% 0.067
SMAD4 mutation – 0.696
Location – 0.745
Prior EBRT – 0.815
Treatment platform
All (Trilogy, Truebeam, CK) – 0.467
Non-robotic (T/T) vs. CyberKnife – 0.163
Recurrent lesion
Recurrent vs. not – 0.586
Surgery (yes vs. no) – 0.124
Dosimetry
GTV volume – 0.664
GTV max dose – 0.380
GTV min dose – 0.694
PTV volume – 0.564
PTV max dose – 0.480
PTV min dose – 0.176
PTV mean dose – 0.900
Small bowel max dose – 0.487
Small bowel mean dose – 0.499
Single vs. multifraction – 0.226
BED10 Gy (continuous) – 0.429
Variable hr (95% ci) p Value
Post-SBRT CA 19-9 1.01 (1.01–1.01) 0.001
Boldface values are significant predictors (p value < 0.05).
TaBle 4 | Univariate and multivariate analysis for regional control (RC).
Variable 2-year rc p Value
Age – 0.271
ca 19-9
At diagnosis – 0.535
Pre-SBRT – 0.413
Post-SBRT – 0.020
By median (≤73 vs. >73) – 0.580
≤90 vs. >90 – 0.891
SMAD4 mutation – 0.677
Location – 0.942
Prior EBRT – 0.677
Treatment platform
All (Trilogy, Truebeam, CK) – 0.735
Non-robotic (T/T) vs. CyberKnife – 0.725
recurrent lesion
Recurrent vs. not – 0.137
Surgery (yes vs. no) – 0.434
Dosimetry
GTV volume – 0.685
GTV max dose – 0.904
GTV min dose – 0.761
PTV volume – 0.752
PTV max dose – 0.958
PTV min dose – 0.608
PTV mean dose – 0.789
Small bowel max dose – 0.748
Small bowel mean dose – 0.600
Single vs. multifraction – 0.541
BED10 Gy (continuous) – 0.067
Variable hr (95% ci) p Value
Post-SBRT CA 19-9 1.01 (1.01–1.01) 0.020
Boldface values are significant predictors (p value < 0.05).
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bowel in an attempt to minimize toxicity rates. Our lack of ability 
to identify differences in toxicity could also be secondary to the 
inherent limitation of retrospective studies.
Stereotactic body radiation therapy has also been identified as 
an effective treatment modality in treatment of recurrent lesions 
following resection. Dagolglu et al. reported on 30 patients treated 
with SBRT for recurrent pancreatic cancer with prior radiation 
therapy. Patients received a median of 25  Gy in five fractions. 
Median OS was 14 months, 2-year LC was 78, and 7% advanced 
grade 3+ toxicity (26). Here, we reported significantly greater risk 
of advanced toxicity with prior radiation therapy while Dagolglu 
et  al. demonstrated reasonable toxicity in patients with prior 
radiation. The lower toxicity seen with Dagolglu et al. could be 
secondary to the five fraction regimen used as opposed to the 
three fractions or one fraction mostly used in our study. Also, 
25 Gy in five fractions has a lower biological effective dose than 
our regimens, which may compromise LC.
Herman et al. recently reported on a multi-institutional study 
combining Gemcitabine with five-fraction SBRT in patients with 
locally advanced pancreatic cancer (27). Forty-nine patients with 
locally advanced patients were treated with up to three doses of 
Gemcitabine (1,000 mg/m2) followed by a 1-week break and then 
SBRT, 33 Gy in five fractions over 1–2 weeks. After SBRT, patients 
were continued on Gemcitabine until progression. Median OS 
was 14  months and 2-year OS was 18%. Freedom from local 
progression at 1-year was 78%. On multivariate analysis PET 
positive disease prior to SBRT and CA19-9 > 90 after SBRT were 
associated with an increased risk of death. Acute grade 2 plus 
toxicity included enteritis, gastritis and ulcer. There was 1 grade 
4 toxicity of a duodenal fistula. There was 11% advanced grade 
2 or greater toxicity, again mostly enteritis, gastritis, and ulcer. 
Their advanced toxicity was low like ours showing feasibility of 
multifraction regimens.
We showed higher post-SBRT CA 19-9 were associated with 
lower survival and higher rates of regional and DM. This is similar 
to the results reported by Herman et al, who showed post-SBRT val-
ues greater than 90 were associated with a lower survival on multi-
variate analysis (27). These results of post-SBRT CA19-9 associated 
with survival but not CA19-9 at diagnosis or pre-SBRT indicate 
posttreatment CA19-9 as a surrogate for treatment efficacy. Similar 
data have been reported in the literature identifying a decrease in 
CA19-9 following treatment to be a predictor of OS (28–30). Future 
trials evaluating the role of SBRT for pancreatic carcinoma should 
consider evaluating the affect SBRT has on CA19-9 values.
This study adds to the current growing body of literature that 
demonstrates the effectiveness and tolerability of SBRT for pancre-
atic adenocarcinoma. Following the initial reports demonstrating 
unacceptably high rates of advanced GI toxicity with single fraction 
SBRT, many institutions transitioned to multifraction regimens. 
TaBle 6 | Kaplan–Meier estimates for various end points.
end point Kaplan–Meier 
estimate (95% 
confidence interval)
Median follow-up
From SBRT (months) (IQ range) 17.3 (10.1–29.3)
Median survival
Median survival (months) (95% CI) 17.8 (15.7–20.0)
12 months (95% CI) 69.7 (64.4–75.0)
24 months (95% CI) 35.3 (29.8–40.9)
local control from sBrT
12 months (95% CI) 73.7 (67.6–79.8)
24 months (95% CI) 66.1 (58.5–73.4)
regional control from sBrT
12 months (95% CI) 89.2 (84.9–93.5)
24 months (95% CI) 86.3 (81.0–91.6)
Distant metastases from sBrT
12 months (95% CI) 39.5 (33.0–46.0)
24 months (95% CI) 56.4 (48.6–64.2)
Toxicity
Grade 2+ toxicity
1-year toxicity (95% CI) 7.8 (4.7–10.9)
2-year toxicity (95% CI) 7.8 (4.7–10.9)
Grade 3+ toxicity
1-year toxicity (95% CI) 2.5 (2.3–2.7)
2-year toxicity (95% CI) 2.5 (2.3–2.7)
Univariable analysis for advanced toxicities
Variable (grade 2+advanced toxicity) hr (95% ci) p Value
Prior radiotherapy 3.26 (1.33–8.00) 0.010
GTV volume – 0.201
PTV volume – 0.736
Treatment platform – 0.57
Single vs. multifraction – 0.737
Small bowel max dose – 0.955
Small bowel mean dose – 0.774
Variable (grade 3+ advanced toxicity) hr (95% ci) p Value
Prior radiotherapy 4.58 (1.29–16.21) 0.019
GTV volume – 0.396
PTV volume – 0.997
Treatment platform – 0.427
Single vs. multifraction – 0.983
Small bowel max dose – 0.899
Small bowel mean dose – 0.795
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Despite previous reports indicating multifraction SBRT produced 
decreased rates of toxicity, it was unclear whether this came at 
the cost of other clinical outcomes. Through analyzing the larg-
est cohort comparing single to multifraction SBRT, we identified 
multifraction treatment schedules to be associated with improved 
LC while reinforcing the significant role surgery and CA19-9 
levels play in prognosis (2, 18, 31–34). These results support the 
continued use of multifraction regimens. Taken together with prior 
work, multifraction SBRT appears to provide either improved LC 
or reduced rates of toxicity as compared to single fraction (20).
Despite the above study showing a significant difference in LC 
between SBRT fractionation, there were numerous limitations to 
this work. Our cohort represented a very heterogeneous popula-
tion as it included resected and unresected disease, recurrent 
disease, as well as patients with prior EBRT. Additionally, as this 
was a retrospective review the breakdown of patients within one- 
and three-fraction SBRT were not matched. Another limitation 
was our inability to capture detailed chemotherapy data on these 
patients. As patients with single fraction were treated in earlier 
years it is possible there is an unseen effect of advancements in 
chemotherapy over time. Regarding toxicity, although we report 
very low rates, this may be artificially low due to uncaptured 
toxicity associated with retrospective reports. However, our low 
toxicity rates are possibly secondary to our institution editing the 
PTV out of the bowel to reduce toxicity. Finally, CA19-9 levels 
and SMAD4 mutation status were not obtained in all patients, 
likely due to limited testing. Prospective studies will be needed to 
provide a more rigorous analysis of the role of SBRT fractionation 
in pancreatic adenocarcinoma as well as the possible contribution 
of SMAD4 mutation status and evolving systemic therapy on LC.
cOnclUsiOn
This single institution retrospective review of 291 patients with 
pancreatic adenocarcinoma identified multifraction regimens 
SBRT had a higher LC than single fractionation regimens. 
Although multifraction regimens displayed a higher OS on uni-
variate analysis it did not hold significance on MVA. Post-SBRT 
CA19-9 was found to be significant factor for OS, RC, and DM. 
Finally, we showed low rates of advanced grade 2+ and grade 3+ 
toxicity associated with SBRT. This single institution report is the 
largest retrospective series showing multifraction regimens SBRT 
is associated with a higher LC than single fractionation regimens.
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